22 Jul AffyImmune Therapeutics
Matt Britz, Chief Operating Officer
Oct. 11 | 4:15pm | Oxford Biomedica Ballroom
AffyImmune is realizing the potential of cancer immunotherapy by extending the anti-cancer activity of CAR T cell therapy to solid tumors. AffyImmune’s proprietary technology allows fine-tuning of the affinity of CAR T cells to reduce toxicity, and a tracking system to allow for real-time localization of CAR T cells after administration to patients. By affinity-tuning CAR T cells to select those targeting overexpressed but non-unique tumor associated antigens, we avoid toxicity to normal cells expressing lower levels of the target. Lower affinity CARs result in activation of CAR T cells in a manner more similar to the natural activation observed in non-engineered T cells. This more physiological activation leads to better serial tumor cell killing, clonal expansion, and long-term persistence to result in greater effectiveness. The company was founded in 2016 and is currently enrolling patients in its Phase I trial to treat advanced thyroid cancer.